18O-Labeled Nucleotides for Localized Proton-Activated Tumor DNA Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional radiation therapy, including proton therapy, affects both healthy and cancerous cells, leading to significant side effects, particularly in children, and the full potential of proton beam therapy has not been realized due to limited availability and effectiveness in treating tumors.
Innovation Solution
Development of non-natural nucleotide derivatives with heavy oxygen (18O) that incorporate into cellular DNA, activated by proton beam therapy to transmute into radioactive 18F, causing chemical breaks in the DNA structure, enhancing treatment sensitivity and allowing for precise targeting of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional radiation therapy or proton therapy is used to treat cancer, then cancer cells are inhibited from growing, but both healthy and cancerous cells are affected causing significant side effects
Solution Approach 1:
The patent incorporates 18O-labeled nucleotides into DNA before proton beam irradiation. These labeled nucleotides are taken up by cancer cells during DNA synthesis, pre-positioning the radioactive isotope within the target cells. When protons strike, the 18O transmutates to 18F locally, delivering radiation precisely where the labeled nucleotides are incorporated - primarily in cancer cells with high DNA synthesis activity - thereby protecting healthy cells from collateral damage
Solution Approach 2:
The invention creates localized radioactive transformation at the site of 18O incorporation within DNA. The proton beam activates 18O to 18F only in regions where the labeled nucleotides have been incorporated, primarily in cancer cells. This localized activation ensures that the harmful radiation effects are concentrated in the tumor tissue while surrounding healthy tissue receives minimal exposure
2Object-affected harmful factors
If proton beam therapy is used to reduce side effects on healthy tissue, then radiation can be more specifically targeted, but the full potential has not been realized due to limited availability and effectiveness
Solution Approach 1:
The patent combines 18O-labeled nucleotides with proton beam therapy to create a composite treatment approach. The 18O-labeled compounds serve as biological vectors that selectively accumulate in cancer cells, while the proton beam provides the activation energy. This composite system enhances the inherent advantages of proton therapy by adding molecular targeting capability, thereby realizing the full potential of proton beam therapy for selective cancer cell destruction
Solution Approach 2:
The invention changes the physical state of 18O from a stable isotope to a radioactive 18F through proton-induced transmutation. This parameter change occurs only when and where the proton beam intersects with cells containing 18O-labeled nucleotides. The transformation from stable to radioactive state creates localized positron emission that can be detected and utilized for both imaging and therapeutic purposes, enhancing treatment effectiveness
3Reliability
If 18O-labeled nucleotides are incorporated into DNA and activated by proton beam, then treatment sensitivity increases and healthy tissue is protected, but the process requires proton beam activation
Solution Approach 1:
The 18O-labeled nucleotides themselves serve as the activation target for the proton beam. The proton beam does not need to carry complex targeting information because the 18O atoms within the incorporated nucleotides act as intrinsic activation sites. When protons pass through tissue, they automatically activate 18O atoms wherever they are incorporated in DNA, eliminating the need for external targeting mechanisms and simplifying the overall system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of 18O-labeled nucleotides with proton beam therapy increases treatment sensitivity and specificity, reducing side effects on healthy tissue and enabling effective imaging and treatment of tumors with lower radiation doses.
Implementation Method 1
the 18O targeting agent is activated by proton treatment. In one aspect, after a compound has incorporated into cellular DNA the 18O targeting agent is activated by proton treatment. In one embodiment, the proton treatment activates the 18O targeting agent and the ensuing particle-nuclear reaction transmutates 18O into 18F.
Implementation Method 2
Protons carry the energy in proton therapy and the protons are raised to a high energy level using a particle accelerator. Both proton therapy and traditional radiation treat malignancies the same way: by inhibiting the growth of cancer cells.
Data Source
AI summary
The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.